Clinical trials: Malignant Tumor
Advanced Solid Tumors
Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules
This is a study to evaluate the effect of high-fat meal on the pharmacokinetics of TQ-B3139 capsules in patients with solid tumor
- Trial name
- NCT04675060
- Testing
- TQ-B3139 capsules
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Prostate Cancer
Study of XNW5004 Tablets in Advanced Prostate Cancer
Phase Ib A preliminary design of 2 cohorts is planned for this phase, with 3-6 participants to be enrolled in each cohort. A total of 6-12 participants with advanced prostate cancer are planned to be enrolled in this phase.
- Trial name
- XNW5004 Tablet (NCT07730580)
- Testing
- XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID
- Volunteers
- 242 people
- Sponsor
- Evopoint Biosciences Inc.
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab…
- Trial name
- abound2L+ (NCT02250326)
- Testing
- nab-paclitaxel IV, CC-486, Duravalumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 240 people
- Sponsor
- Celgene
Malignant Pleural Effusion
A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
A Phase I, Open, Multicenter Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
- Trial name
- NCT05923515
- Testing
- JMKX000197
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Jemincare
Merkel Cell Carcinoma
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
Phase 2, single-arm study to evaluate combination therapy of avelumab, haNK and N-803 in patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor therapy as assessed by ORR.
- Trial name
- NCT03853317
- Testing
- Avelumab, N-803, haNK™
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- ImmunityBio, Inc.
Advanced Solid Tumor
A Study of CM350 in Patients With Advanced Solid Tumors
This is an open label, dose escalation and expansion Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of CM350 in patients with advanced solid…
- Trial name
- NCT05263960
- Testing
- CM350 group1, CM350 group2, CM350 group3
- Where
- 2 sites in China
- Volunteers
- 248 people
- Sponsor
- Keymed Biosciences Co.Ltd
Brain Tumor Adult, Low Grade Glioma (LGG), High Grade Glioma (HGG)
A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery
The objective of this clinical investigation is to assess the safety and performance of the SonoClear® System. Performance will be assessed by analysis of the contrast-to-noise ratio (CNR) and assessment of image quality by using…
- Conditions
- Brain Tumor Adult, Low Grade Glioma (LGG), High Grade Glioma (HGG), Glioblastoma
- Trial name
- NCT07042620
- Testing
- SonoClear(R) System
- Where
- 4 sites in Germany
- Volunteers
- 15 people
- Sponsor
- SonoClear AS
Solid Tumor
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
Primary Objective: To assess the effect of 15-day repeated oral doses of 500 mg SAR302503 on the cytochrome P450 activity using a CYP probe cocktail (2C19, 2D6 and 3A4).
- Trial name
- NCT01585623
- Testing
- SAR302503, omeprazol, metoprolol
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma
A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)
The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral vorinostat in patients with malignant lymphoma.
- Trial name
- NCT00127140
- Testing
- vorinostat
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms, Germ Cell and Embryonal
Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin
To evaluate the efficacy of the oxaliplatin-paclitaxel combination i.e. evaluation of tumor response rate using World Health Organization/Union Internationale Contre le Cancer (WHO/UICC) and Indianapolis tumor marker (human…
- Trial name
- NCT00611962
- Testing
- Oxaliplatin, Paclitaxel
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Sanofi
Solid Tumor
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
BBI-825 is a potent, selective, oral, small molecule inhibitor of ribonucleotide reductase (RNR). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to determine the safety profile and identify the…
- Trial name
- STARMAP (NCT06299761)
- Testing
- BBI-825
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Boundless Bio, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06797986
- Testing
- BVAC-E6E7 (low level), BVAC-E6E7 (high level), BVAC-E6E7 (RP2D)
- Where
- 2 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- Cellid Co., Ltd.
Carcinoma, Non-Small-Cell Lung
MYLUNG Consortium Study Protocol 2
This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced…
- Trial name
- MYLUNG (NCT05644808)
- Where
- 18 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- US Oncology Research
Non Small Cell Lung Cancer
FRAME-001 Personalized Vaccine in NSCLC
Despite encouraging results of programmed cell death protein -1 (PD-1) immune checkpoint inhibitor treatment combined with chemotherapy in advanced non-small cell lung cancer (NSCLC), only the minority of approximately 20% of…
- Trial name
- NCT04998474
- Testing
- FRAME-001 personalized vaccine
- Where
- 3 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Frame Pharmaceuticals B.V.
Locally Advanced Pancreatic Adenocarcinoma
Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)
The EF-54 program (PANOVA-3CA) is a continued access program for adults with locally advanced pancreatic cancer to access TTFields therapy in combination with gemcitabine and nab-paclitaxel.
- Trial name
- PANOVA-3CA (NCT07319910)
- Testing
- TTFields, Gemcitabine, Nab paclitaxel
- Sponsor
- NovoCure GmbH
Malignant Glioma, High-Grade Gliomas
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
This is a draft, ClinicalTrials.gov-style example record for a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent…
- Conditions
- Malignant Glioma, High-Grade Gliomas, Glioblastoma, Recurrent High-Grade Gliomas
- Trial name
- NCT07551336
- Testing
- Dual-target CAR-NK cells, Cyclophosphamide, Intracranial catheter/reservoir for locoregional delivery
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Malignant Solid Tumor
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with…
- Trial name
- NCT05859464
- Testing
- ZL-1218, Pembrolizumab
- Where
- 15 sites in United States, China and 1 more
- Volunteers
- 34 people
- Sponsor
- Zai Lab (Hong Kong), Ltd.
Malignant Melanoma
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
This multicenter, open-label study will assess the safety and pharmacokinetics of DEDN6526A in patients with metastatic or unresectable melanoma.
- Trial name
- NCT01522664
- Testing
- DEDN6526A
- Where
- 6 sites in United States, Australia
- Volunteers
- 53 people
- Sponsor
- Genentech, Inc.
Prostate Cancer
Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level
Prostate cancer screening with PSA is plagued by high rate of unnecessary prostate biopsies, especially in the "gray zone" (4.00ng/ml e 10.99ng/ml).
- Trial name
- NCT03488706
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- CellMaxLife
Solid Tumor
HS-IT201 Injection in the Treatment of Advanced Solid Tumors
Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT201) after lymphodepletion preparative with fludarabine and cyclophosphamide…
- Trial name
- NCT06613152
- Testing
- HS-IT201 Injection
- Volunteers
- 9 people
- Sponsor
- Hangzhou Huasai Biomedicine Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.